시장보고서
상품코드
1687538

유도만능줄기세포 생산 시장 규모, 점유율, 성장 분석 : 프로세스별, 워크플로우별, 제품별, 용도별, 최종 용도별, 지역별 - 산업 예측(2025-2032년)

Induced Pluripotent Stem Cells Production Market Size, Share, and Growth Analysis, By Process (Manual, Automated), By Workflow (Reprogramming, Cell Culture), By Product, By Application, By End-Use, By Region - Industry Forecast 2025-2032

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 219 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

유도만능줄기세포 생산 시장 규모는 2023년에 15억 3,000만 달러로, 2024년 16억 8,000만 달러에서 2032년에는 34억 9,000만 달러로 확대하며, 예측 기간(2025-2032년)의 CAGR은 9.6%로 성장할 전망입니다.

줄기세포(iPSC) 제조 시장은 재생의료 및 세포치료 분야에서 괄목할 만한 성장과 혁신을 이루고 있습니다. 성체 세포에서 유도되어 다능성 상태로 재프로그래밍된 iPSC는 개인 맞춤형 치료와 질병 모델링에 큰 잠재력을 제공합니다. 이 급성장하는 시장은 신약개발과 다양한 질환에 대한 iPSC의 적용에 대한 이해도가 높아짐에 따라 성장하고 있습니다. R&D 및 생명공학 기업은 확장 가능하고 비용 효율적인 iPSC 생산을 위한 효율적인 기술을 적극적으로 개발하고 있습니다. 학계, 산업계, 의료기관의 협업이 진보를 촉진하는 한편, 엄격한 규제 프레임워크와 윤리적 고려사항은 표준화된 방법론의 필요성을 강조하는 환경을 조성하고 있습니다. 세계 헬스케어의 발전과 함께 iPS 세포 제조 시장은 지속적으로 확대될 것이며, 과학적 혁신과 치료 솔루션의 길을 열어줄 것입니다.

목차

서론

  • 조사의 목적
  • 조사 범위
  • 정의

조사 방법

  • 정보 조달
  • 2차와 1차 데이터 방법
  • 시장 규모 예측
  • 시장의 전제조건과 제한

개요

  • 세계 시장 전망
  • 공급과 수요 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 촉진요인과 기회
    • 억제요인과 과제
  • Porter의 산업 분석

주요 시장 인사이트

  • 주요 성공 요인
  • 경쟁의 정도
  • 주요 투자 기회
  • 시장 에코시스템
  • 시장의 매력 지수(2024년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석
  • 사례 연구
  • 규제 상황

유도만능줄기세포 생산 시장 규모 : 프로세스별 & CAGR(2025-2032)

  • 시장 개요
  • 매뉴얼
  • 자동화

유도만능줄기세포 생산 시장 규모 : 워크플로우별 & CAGR(2025-2032)

  • 시장 개요
  • 재프로그래밍
  • 세포배양

유도만능줄기세포 생산 시장 규모 : 제품별 & CAGR(2025-2032)

  • 시장 개요
  • 소모품과 키트
  • 기기
  • 서비스

유도만능줄기세포 생산 시장 규모 : 용도별 & CAGR(2025-2032)

  • 시장 개요
  • 의약품 개발과 발견
  • 재생의료
  • 독성학 연구
  • 질환 모델
  • 기타

유도만능줄기세포 생산 시장 규모 : 최종 용도별 & CAGR(2025-2032)

  • 시장 개요
  • 학술 조사기관
  • 바이오테크놀러지·제약회사
  • 병원·클리닉

유도만능줄기세포 생산 시장 규모 : 지역별 & CAGR(2025-2032)

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽 지역
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카 지역
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 정보

  • 상위 5사의 비교
  • 주요 기업의 시장 포지셔닝(2024년)
  • 주요 시장 기업이 채택한 전략
  • 최근 시장 동향
  • 기업의 시장 점유율 분석(2024년)
  • 주요 기업의 기업 개요
    • 기업의 상세
    • 제품 포트폴리오 분석
    • 기업의 부문별 점유율 분석
    • 매출의 전년대비 비교(2022-2024)

주요 기업 개요

  • FUJIFILM Cellular Dynamics(USA)
  • Astellas Pharma(Japan)
  • Thermo Fisher Scientific(USA)
  • Takara Bio(Japan)
  • Lonza Group(Switzerland)
  • Merck KGaA(Germany)
  • ReproCELL(Japan)
  • STEMCELL Technologies(Canada)
  • Fate Therapeutics(USA)
  • Cynata Therapeutics(Australia)
  • Axol Bioscience(UK)
  • Ncardia(Belgium)
  • Pluricell Biotech(Brazil)
  • Evotec(Germany)
  • BioTime(USA)
  • Cellular Engineering Technologies(USA)
  • StemoniX(USA)
  • BrainXell(USA)
  • EMD Millipore(USA)
  • R&D Systems(USA)

결론과 제안

KSA 25.04.24

Induced Pluripotent Stem Cells Production Market size was valued at USD 1.53 billion in 2023 and is poised to grow from USD 1.68 billion in 2024 to USD 3.49 billion by 2032, growing at a CAGR of 9.6% during the forecast period (2025-2032).

The triggered pluripotent stem cell (iPSC) manufacturing market is experiencing remarkable growth and innovation within regenerative medicine and cellular therapy. Derived from adult cells and reprogrammed into a pluripotent state, iPSCs offer significant potential for personalized treatments and disease modeling. This burgeoning market is fueled by an increasing understanding of iPSCs' applications in drug discovery and various medical conditions. Researchers and biotech firms are actively developing efficient techniques for scalable and cost-effective iPSC production. Collaborations among academia, industry, and healthcare institutions are driving advancements, while stringent regulatory frameworks and ethical considerations shape the landscape, highlighting the need for standardized practices. As global healthcare evolves, the iPSC manufacturing market is set for continued expansion, paving the way for scientific breakthroughs and therapeutic solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Induced Pluripotent Stem Cells Production market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Induced Pluripotent Stem Cells Production Market Segments Analysis

Global Induced Pluripotent Stem Cells Production Market is segmented by Process, Workflow, Product, Application, End-Use and region. Based on Process, the market is segmented into Manual and Automated. Based on Workflow, the market is segmented into Reprogramming and Cell Culture. Based on Product, the market is segmented into Consumables & Kits, Instruments and Services. Based on Application, the market is segmented into Drug Development & Discovery, Regenerative Medicine, Toxicology Studies, Disease Modeling and Others. Based on End-Use, the market is segmented into Academic & Research Institutes, Biotechnology & Pharmaceutical Companies and Hospitals & Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Induced Pluripotent Stem Cells Production Market

A significant driving force behind the global induced pluripotent stem cells (iPSC) production market is the ongoing advancements in regenerative medicine. These stem cells present substantial potential for creating personalized and effective treatments for various medical conditions, thereby attracting significant investment in research and development. Such innovations not only broaden the applications of iPSCs but also present novel therapeutic options, which significantly propel market growth. The increasing interest from pharmaceutical companies and healthcare institutions further enhances this trend, underscoring the pivotal role that advancements in regenerative medicine play in fostering market expansion and stimulating continued investment in iPSC technologies.

Restraints in the Induced Pluripotent Stem Cells Production Market

One significant constraint facing the global induced pluripotent stem cells (iPSC) production market is the array of ethical and regulatory hurdles. Issues regarding the use of human-derived materials, coupled with concerns about the potential misuse of iPSC technology, have led to the implementation of strict regulations in various regions. These obstacles can impede research initiatives, raise compliance costs, and generate market uncertainty. Consequently, such factors can hinder the pace of iPSC adoption and commercialization, ultimately affecting the growth and development of this promising sector in regenerative medicine and biotechnology.

Market Trends of the Induced Pluripotent Stem Cells Production Market

The global Induced Pluripotent Stem Cells (iPSC) production market is witnessing a significant trend driven by the emergence of iPSC-based disease modeling. Researchers and pharmaceutical companies are increasingly leveraging iPSC technology to develop disease-specific cell lines, facilitating more accurate and personalized modeling of a variety of diseases, including genetic disorders, neurodegenerative conditions, and cardiovascular diseases. This shift not only enhances drug discovery and development processes but also fosters the emergence of targeted and effective therapeutic strategies, ultimately shaping the future landscape of precision medicine. As a result, the demand for iPSC products is expected to surge, propelling market growth in the coming years.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies
  • Regulatory Landscape

Global Induced Pluripotent Stem Cells Production Market Size by Process & CAGR (2025-2032)

  • Market Overview
  • Manual
  • Automated

Global Induced Pluripotent Stem Cells Production Market Size by Workflow & CAGR (2025-2032)

  • Market Overview
  • Reprogramming
  • Cell Culture

Global Induced Pluripotent Stem Cells Production Market Size by Product & CAGR (2025-2032)

  • Market Overview
  • Consumables & Kits
  • Instruments
  • Services

Global Induced Pluripotent Stem Cells Production Market Size by Application & CAGR (2025-2032)

  • Market Overview
  • Drug Development & Discovery
  • Regenerative Medicine
  • Toxicology Studies
  • Disease Modeling
  • Others

Global Induced Pluripotent Stem Cells Production Market Size by End-Use & CAGR (2025-2032)

  • Market Overview
  • Academic & Research Institutes
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics

Global Induced Pluripotent Stem Cells Production Market Size & CAGR (2025-2032)

  • North America (Process, Workflow, Product, Application, End-Use)
    • US
    • Canada
  • Europe (Process, Workflow, Product, Application, End-Use)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Process, Workflow, Product, Application, End-Use)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Process, Workflow, Product, Application, End-Use)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Process, Workflow, Product, Application, End-Use)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • FUJIFILM Cellular Dynamics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takara Bio (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lonza Group (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ReproCELL (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • STEMCELL Technologies (Canada)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fate Therapeutics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cynata Therapeutics (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Axol Bioscience (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ncardia (Belgium)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pluricell Biotech (Brazil)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Evotec (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioTime (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cellular Engineering Technologies (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • StemoniX (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BrainXell (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • EMD Millipore (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • R&D Systems (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제